Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
In the SURMOUNT 1 trial, tirzepatide at doses of 5 mg, 10 mg and 15 mg were evaluated against placebo, with pooled tirzepatide groups resulting in significant decreases in total cholesterol, LDL-C, VLDL-C, FFA, and triglycerides and an increase in HDL-C at week 72 of follow-up [35]
LDN, Nordhorn, Germany)
MRS data acquisition and analysis Spectra were obtained on a 3T GE Discovery MR750 (SW: DV26 R01) scanner from two regions of interest: anterior cingulate cortex (ACC) and left dorsolateral prefrontal cortex (DLPFC) (Figure 1)
Key Insight: The results are not guaranteed for everyone
US$ 20.69
US$ 20.84
US$ 22.60
US$ 24.91
US$ 24.93
